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Abstract
Objective—To determine the impact of age and initial HAART regimen class on virologic and
immunologic response within 24 months after initiation.
Design—Pooled analysis of data from 19 prospective cohort studies in the North American AIDS
Cohort Collaboration on Research and Design (NA-ACCORD).
Methods—Twelve thousand, one hundred and ninety-six antiretroviral-naive adults who initiated
HAART between 1998 and 2008 using a boosted protease inhibitor-based regimen or a
nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen were included in our study.
Discrete time-to-event models estimated adjusted hazard odds ratios (aHOR) and 95% confidence
intervals (CIs) for suppressed viral load (≤500 copies/ml) and, separately, at least 100 cells/μl
increase in CD4 cell count. Truncated, stabilized inverse probability weights accounted for
selection biases from discontinuation of initial regimen class.
Results—Among 12 196 eligible participants (mean age = 42 years), 50% changed regimen
classes after initiation (57 and 48% of whom initiated protease inhibitor and NNRTI-based
regimens, respectively). Mean CD4 cell count at initiation was similar by age. Virologic response
to treatment was less likely in those initiating using a boosted protease inhibitor [aHOR = 0.77
(0.73, 0.82)], regardless of age. Immunologic response decreased with increasing age [18–<30:
ref; 30–<40: aHOR 0.92 (0.85, 1.00); 40–<50: aHOR = 0.85 (0.78, 0.92); 50–<60: aHOR = 0.82
(0.74, 0.90); ≥60: aHOR=0.74 (0.65, 0.85)], regardless of initial regimen.
Conclusion—We found no evidence of an interaction between age and initial anti-retroviral
regimen on virologic or immunologic response to HAART; however, decreased immunologic
response with increasing age may have implications for age-specific when-to-start guidelines.
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Introduction
The proportion of Americans who are HIV-infected and older than 50 is growing. By 2015,
more than 50% of all adults with HIV in the United States will be age at least 50 years [1,2].
It is believed this increasing proportion of HIV-infected individuals who are age at least 50
years is driven by increased survival owing to HAART [3]. New infections also contribute
to the increase in HIV-infected adults aged at least 50 years, occurring at an estimated rate
of 6.5 per 100 000 population [2].
Although it is generally thought that older HIV-infected individuals initiating HAART will
have a decreased immunological response [4–7,13–16] and an increased virologic response
[4–12] compared with younger individuals, published data regarding immunologic and
virologic response by age to HAART has been mixed. Some studies have demonstrated a
smaller increase in CD4 cell count in older compared with younger adults [4–7,13–16],
whereas others have been equivocal [10,12,17–19]. Some studies have demonstrated
increased virologic suppression in older compared with younger adults [4–12] (which was
hypothesized to be adherence-driven [5,20]), whereas one study reported the reverse [21],
and many other studies have reported no differences [13,15–17,19]. Current guidelines
recommend the initiation of HAART using either ritonavir-boosted protease inhibitors or
nonnucleoside reverse-transcriptase inhibitors (NNRTI) [22,23]. These guidelines do not
differentiate the recommendations by age, but there were a limited number of older
individuals who contributed data to the studies that informed these guidelines. Of the
participants in the largest randomized trial of initial HAART regimen class on HIV-1 RNA
viral suppression, only 12% were age at least 50 years [24]. Similarly, the largest
randomized trial of initial HAART regimen class on immunologic response had a median
age of 38 years (interquartile range 32–44) [25].
Given the increasing number of individuals aged at least 50 years with HIV, it is important
to determine if HIV antiretroviral guidelines should reflect age differences in virologic and
immunologic response to HAART by regimen class. No study has evaluated immunologic
and virologic response to HAART by both initial regimen class and age. Thus, the objective
of this study was to evaluate the short-term virological and immunologic response to
HAART by age and initial regimen class.
Methods
Study population and design
Owing to the large sample size needed to determine the interaction of age and HAART
regimen class, our study was nested in the North American AIDS Cohort Collaboration on
Research and Design (NA-ACCORD), a collaboration of eight interval and 13 clinical
prospective cohort studies of demographically heterogeneous HIV-infected adults from the
United States and Canada. The NA-ACCORD is a regional group of the International
Epidemiological Databases to Evaluate AIDS (IeDEA) project with over 60 study sites in
the United States and Canada. Details of the collaboration have been described elsewhere
[26]. Briefly, contributing cohorts have used standardized methods of data collection and
have submitted demographic, treatment, clinical, laboratory, and vital status data on enrolled
participants. Each cohort's participation in NA-ACCORD was approved by the respective
local institutional review boards.
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Nineteen NA-ACCORD cohorts contributed the necessary data and agreed to participate in
this study. Participants who were at least 18-year-old from these cohorts were included in
our study if they initiated HAART using a boosted protease inhibitor-based or NNRTI-based
regimen in combination with two or more NRTIs between January 1 1998 and December 31
2008. Those initiating HAART using only nucleoside analogues, nonboosted protease
inhibitors, or dual protease inhibitor-NNRTI regimens were excluded from the study.
Individuals were required to have at least one follow-up visit; those who discontinued or
changed regimens in the first month following HAART initiation were excluded. Further, all
participants had a pre-HAART CD4 cell count and HIV-1 RNA measured at, or within 6
months prior to, HAART initiation. Lastly, to most appropriately examine the impact of the
initial HAART regimen on our immunologic and virologic outcomes of interest, individuals
with a record of treatment prior to HAART initiation, or an HIV-1 RNA at least 500 copies/
ml at HAART initiation were excluded.
Outcomes: immunologic and virologic response
Virologic and immunologic responses were measured up to 24 months following HAART
initiation. Virologic response was measured using plasma HIV-1 RNA concentrations.
Because of differences in HIV-1 RNA assays used in contributing cohorts over time, we
defined an HIV-1 RNA measure of 500 copies/ml or less (`suppressed') as the virologic
endpoint of interest. If a viral load result was reported as undetectable with an assay that
used a lower limit of detection more than 500 copies/ml that measurement was discarded
(<1% of all viral load measurements). Immunologic response was measured by CD4 cell
count as reported by the cohorts. Time to an increase of 100 cells/μl relative to CD4 cell
count at, or within 6 months prior to HAART initiation, was used in analyses as a clinically
important response. If an individual had more than one HIV-1 RNA or CD4 cell count
measurement within a month, the lowest HIV-1 RNA measurement and the arithmetic mean
of the CD4 cell measurements were used.
Exposures: age at HAART initiation and initial HAART regimen class
Age at HAART initiation was calculated using the year of birth and the date of HAART
initiation and was stratified into five groups 18–<30 years, 30–<40 years, 40–<50 years, 50–
<60 years and at least 60 years. HAARTwas defined as a regimen containing at least three
antiretroviral drugs from two or more classes including a boosted protease inhibitor and/or
NNRTI. Initial HAART regimen class was specified as the class used at initiation of
HAART (boosted protease inhibitor or NNRTI).
Other covariates of interest
Demographic and variables related to HIV disease progression were measured as possible
confounders. Demographic variables included sex and race (White, Black, Latino or other/
unknown). HIV transmission risk factor was categorized as men who have sex with men
(MSM), history of injection drug use (IDU), heterosexual, or other/unknown. Individuals
reporting IDU and either male-to-male sexual risk or heterosexual risk were classified as
IDU. Other potential confounders included pre-HAART clinically diagnosed AIDS-defining
illness (according to the 1993 criteria of the Centers for Disease Control and Prevention
(CDC) excluding CD4 cell count less than 200 cells/μl), year of HAART initiation, sex and
cohort. Data regarding time from HIV seroconversion and nadir CD4 cell count were not
available.
Statistical analysis
Differences in means and proportions by age were tested using the chi-squared test statistics
and ANOVA, respectively.
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Using observational data, we conducted analyses that mimic `as-treated' analyses in clinical
trials with imperfect compliance [27]. To accomplish this aim, we followed individuals from
the time of HAART initiation in monthly intervals until the outcome of interest, `regular'
censoring consisting of the date of the last CD4 cell measurement, death, or December 31,
2008; or `discontinuation' censoring reflecting the date discontinuation of, or switch from,
the initial HAART regimen class.
Discontinuation censoring may induce a selection bias because only those individuals who
do not discontinue or change from their regimen remain in the study population [28]. To
correct this bias, weights were used to allow for influence of those who are censored owing
to discontinuation, thus reducing the selection bias [28,29]. Details regarding the estimation
and use of published methods [28] are provided in the Appendix,
http://links.lww.com/QAD/A71. Adjusted hazards odds ratios (aHOR) and 95% confidence
intervals were estimated for the initial HAARTregimen classes using weighted pooled
logistic regression models with month as the interval of time. Kaplan–Meier estimates of the
cumulative incidence of each outcome by age group were calculated, incorporating
discontinuation and censoring weights [30]. To complement this analysis, we also conducted
an `intention-to-treat' analysis that did not censor at discontinuation or incorporate weights.
Analyses were performed using SAS 9.2 (Cary, North Carolina, USA) and a P-value of less
than 0.05 was used to identify statistically significant variables.
Results
Nineteen NA-ACCORD cohorts participated in our study, contributing 116 619 possible
participants. Of these, 25 449 participants initiated HAART with a boosted protease
inhibitor-based or NNRTI-based regimen between January 1, 1998 and December 31, 2008.
Eight thousand, one hundred and eighty-five participants were excluded owing to lack of
HIV-1 RNA or CD4 cell measurement at, or within 6 months prior to, HAART initiation
and 2903 participants were excluded owing to an HIV-1 RNA 500 copies/ml or less at, or
within 6 months prior to HAART initiation. Eleven participants were excluded because they
were less than 18-years-old at HAART initiation. Finally, 1541 were excluded for failing to
maintain their initial regimen for at least one month and 613 were excluded for not having at
least one visit in 24 months after HAART initiation and prior to the date of administrative
censoring (December 31 2008), resulting in 12 196 eligible participants in our study
population.
The mean age of the study population was 42 years (range 18, 83). The participants were
predominantly male, and the proportion of males increased with increasing age (Table 1).
The proportion of participants who had a history of IDU was greatest among the 40–59 year-
old (21%). Mean CD4 and HIV-1 RNA levels at HAART initiation ranged between 205–
250 cells/μl and 4.66–4.73 log10 copies/ml, respectively, across age groups. The proportion
of adults with a clinical AIDS diagnosis prior to HAART ranged from 14–17% across the
age groups. Overall, 29% of participants initiated HAART on a boosted protease inhibitor-
based regimen and 71% on an NNRTI-based regimen.
Half (50%) (6134/12 196) of individuals did not remain on their initial therapy regimen
class 24 months after initiation; 25% (3100/12 169) changed regimen class and 25%
(3034/12 196) discontinued treatment. Of all the individuals who did not remain on their
initial therapy regimen for 24 months after initiation, 43% (2645/6134) changed regimen
class or discontinued treatment in the first 6 months after HAART initiation. Those initiating
HAART at the oldest ages had the smallest proportion that changed regimen classes or
discontinued treatment (18–<30 years: 51%; 30–<40 years: 50%; 40–<50 years: 52%; 50–
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<60 years: 50%; ≥60 years: 44%; P-value <0.01) and a greater proportion of individuals
who initiated HAART using a boosted protease inhibitor-based regimen changed regimen
class or discontinued treatment (57%) compared with individuals initiating using an NNRTI-
based regimen (48%, P-value<0.01).
The cumulative incidence of HIV-1 RNA 500 copies/ml or less did not differ by age, even
after stratifying by initial regimen (Fig. 1). The cumulative incidence of an increase of at
least 100 cells/μl differed by age with older individuals less likely to achieve this
immunologic response (Fig. 2). The difference in immunologic response by age was seen
among both boosted protease inhibitor and NNRTI initiators.
The results of the pooled logistic regression models are shown in Table 2. The occurrence of
HIV-1 RNA suppression increased with increasing age, however, these estimates were not
statistically significant. Immunologic response decreased with increasing age and the
estimates were statistically significant. Those who initiated using a boosted protease
inhibitor had a decrease in the hazard odds of virologic response compared with those who
initiated using an NNRTI; additionally, there was not a significant increase in the likelihood
of immunologic response on those initiating with boosted protease inhibitors compared with
NNRTIs. Those with higher HIV-1 RNA levels at HAART initiation, Blacks, those in HIV
risk groups other than MSM, and those initiating HAART in the late 1990s and early 2000s
had a decrease in the hazard odds of HIV-1 RNA 500 copies/ml or less. Males, those with a
lower HIV-1 RNA level at HAART initiation, those in HIV risk groups other than MSM,
and those initiating HAART in the late 1990s and early-tomid 2000s had a decrease in the
hazard odds of immunologic response.
The interaction of age and initial HAART regimen class was not statistically significant for
our virologic outcome (P=0.40) or immunologic outcome (P=0.19). The increase in the
hazard odds of viral suppression comparing NNRTI to boosted protease inhibitor was seen
across all age groups (Table 3). The decrease in the hazard odds of immunologic response
with increasing age was seen after stratification by initial regimen.
An intention-to-treat analysis that did not censor individuals at discontinuation or
incorporate weights demonstrated similar findings, but, as expected, were attenuated. For
example, those initiating on boosted protease inhibitors had a 21% decrease in the likelihood
of viral suppression compared with those initiating on an NNTRI [HOR=0.79 (0.75, 0.83)]
and immunologic response decreased with increasing age [18–<30 years: ref; 30–<40 years:
aHOR=0.91 (0.84, 0.98); 40–<50 years: aHOR=0.86 (0.80, 0.93); 50–<60 years:
aHOR=0.90 (0.82, 0.99); ≥60: aHOR=0.81 (0.71, 0.92)]. Age did not modify the effect of
initial regime on virologic or immunologic response (P=0.11 and P=0.35, respectively).
Discussion
This is the largest study of the impact of age and regimen class on virologic and
immunologic response to HAART to date. Our study has several important findings. First,
half (50%) of individuals who initiated therapy discontinued or changed their initial regimen
within the first 2 years. Individuals initiating using an NNRTI-based regimen were more
likely to achieve virologic suppression (HIV-1 RNA ≤500 copies/ml) than those initiating
using a boosted protease inhibitor-based regimen; however, we did not see a significant
increase in virologic suppression with increasing age. In contrast to the virologic outcome,
the immunologic outcome did not differ by regimen class, but was clearly impacted by age
with older individuals less likely to have an increase in of at least 100 cells/μl. Age at
HAART initiation did not modify the effect of the initial regimen on virologic or
immunologic response.
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The estimation of 50% of individuals discontinuing or changing their initial HAART
regimen is an underestimation of the proportion that discontinues, or changes, his/her initial
HAART regimen in the first 2 years because our inclusionary criteria required that an
individual must continue their initial regimen for at least 1 month. Notably, 25% changed
regimen class, suggesting potential side-effect or toxicity, whereas 25% discontinued
treatment for at least 1 month suggesting potential nonadherence. We found a greater
proportion of individuals who initiated HAART using a boosted protease inhibitor-based
regimen changed regimen class or discontinued treatment compared with individuals
initiating using an NNRTI-based regimen (57 and 48%, respectively). Similarly, in a
randomized trial with immunologic outcomes, the proportion that discontinued or changed
from their initial HAART regimen class was 43 and 32% for those who initiated using
protease inhibitor and NNRTI regimens, respectively [25]. This could be because protease
inhibitors are more difficult to tolerate than NNRTIs with side-effects including diarrhea,
hyperlipidemia and glucose dysmetabolism. Studies examining time to toxicity outcomes by
age and HAART regimen class are needed to further assess the need for age-specific
treatment guidelines.
Our data did not show improved virologic response in older patients compared with younger
age groups, as been previously shown [4–12]. Previous studies concluded improved
virologic response among older adults was owing to better adherence to HAART, and
Silverberg et al. [5], found that controlling for adherence mitigated the differences in
virologic responses between age groups [5,20]. Although we were unable to measure and
directly account for adherence in our study, our inclusionary criteria and censoring at the
time of discontinuation of, or change from, initial HAART regimen resulted in a study
population that is more likely to be adherent, regardless of age. Our study criteria for
participation and our methods to account for changes in initial HAART regimen were
necessary to achieve our objective of estimating the average causal effect of initial HAART
regimens on immunologic and virologic response by age. Our findings were similar to the
findings of a randomized-controlled trial of viral suppression by initial ART regimen at 96
weeks, with those initiating using NNRTIs more likely to suppress compared with those
initiating using boosted protease inhibitors [24].
CD4 cell recovery has been shown to be inversely associated with age and other groups have
also found a depressed immunologic response in older patients [12,31,32]. Several
mechanisms may account for the suboptimal immunologic response in older individuals,
including reduced T-cell regenerative capacity owing to either thymic dysfunction and/or the
exhaustion of stem cells, naive T cells or central memory T cells. Chronic inflammation may
also affect T-cell regeneration. The fact that our findings did not differ by regimen class
provides additional evidence for a more broadly defined mechanism for the impact of age on
immunologic response to HAART. Although further research is needed to determine if
guidelines for when to start HAART should differ by age, our observation that older
individuals are less likely to have a robust immunologic response suggest that the optimal
time to start HAART might differ by age.
Although a few studies have looked at the effect of regimen on clinical response by age
group [5,12], no study has examined the effect of regimen type on clinical response in a
population this large or heterogeneous. Bartlett et al. [33], suggested NNRTI-based
regimens were associated with improved virologic suppression compared with protease
inhibitor-based regimens, but did not comment on how this effect might vary with age.
Patterson et al. [11], found immune reconstitution and viral suppression did not vary by
treatment regimen when stratified by age. Our results demonstrate an increase in virologic
response with NNRTI-based regimens compared with protease inhibitor-based regimens,
regardless of age. Although this may suggest that NNRTIs might be preferred in this older
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group, efavirenz, the current guideline-preferred NNRTI, has known CNS adverse effects
that also might cause it to be a less desirable drug in some older patients. Studies examining
time to side-effect and comorbidity events by age and initial HAART regimen class are
needed to further assess the need for age-specific treatment guidelines.
Strengths of this study include the large study population of antiretroviral therapy naïve
adults coupled with modern analytical methods to account for the possible selection biased
induced by censoring individuals once they discontinued or changed their initial HAART
regimen. We did not have data on time from seroconversion to distinguish those who were
infected recently from those who have aged with HIV. Survival is suspected to be the driver
of the greater proportions of HIV-infected individuals who are older, but it is not the only
mechanism. Theoretically, older individuals with HIV infection may have had their infection
longer than younger individuals, and these differences may have contributed to the age-
related effects on immunologic response. Another limitation was using a definition of viral
suppression (<500 copies/ml) that is higher than current standards (<200 copies/ml);
however, owing to the changes in the lower limit detection of HIV-1 RNA assays during our
study time period, using a lower limit of detection cut-off of 200 copies/ml resulted in
omitting 115 050 (8%) viral load measurements, creating a bias by removing many of the
participants from the earlier years of our study. Additionally, we did not have data on the
reason for the switch or discontinuation. Reasons for switching are important for future
studies that could examine differences in toxicity by age and regimen. Lastly, we did not
have a direct measurement of adherence, such as drug plasma levels; however, we suspect
our study criteria and design restricted the study population to the more adherent HIV-
infected individuals.
HIV is a chronic disease that requires life-long therapy and optimizing initial HAART
regimen is important. Although future studies will need to evaluate the impact of toxicity
and non-AIDS-related comorbidities on virologic and immunologic outcomes, our data do
not currently support the use of specific HAART regimens for specific age groups.
However, given the impact of CD4 cell count on long-term survival, initiating HAART at
higher CD4 cell counts for older individuals may be useful given the decreased likelihood of
a robust (≥100 cells/μl) CD4 cell response with increasing age.
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Fig. 1. Cumulative incidence of HIV RNA at least 500 copies/ml in the first 2 years after HAART
initiation, by age group and initial HAART regimen class
(a) Overall cumulative incidence of HIV RNA 500 copies/ml or less in the first 2 years after
HAART initiation. (b) Cumulative incidence of HIV RNA 500 copies/ml or less in those
initiating HAART with a boosted PI-based regimen. (c) Cumulative incidence of HIV RNA
500 copies/ml or less in those initiating HAART with an NNRTI-based regimen. HAART
highly active antiretroviral treatment, NNRTI nonnucleoside reverse transcriptase inhibitor,
PI protease inhibitor.
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Fig. 2. Cumulative incidence of an increase in CD4 cells of at least 100 cells/ml in the first 2 years
after HAART initiation, by age group and initial HAART regimen class
(a) Overall cumulative incidence of at least 100 cells/ml in the first 2 years after HAART
initiation. (b) Cumulative incidence of an increase of at least 100 cells/ml in those initiating
HAART with a boosted PI-based regimen. (c) Cumulative incidence of an increase of at
least 100 cells/ml in those initiating HAART with NNRTI-based regimen. NNRTI
nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor.
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Table 2
Adjusteda hazard odds ratios (aHOR) and 95% confidence intervals (95% CI) of virologic and immunologic
response to HAART within 24 months following HAART initiation, NA-ACCORD, 1998–2008.
Outcomes HIV-1 RNA
suppression (<500 copies/ml)
CD4 cell count increase of 100
cells/μl
aHORa 95% CI aHORa 95% CI
Age (years)
 18–<30 REF - REF -
 30–<40 0.71 0.89–1.05 0.92 0.85–1.00
 40–<50 0.66 0.89–1.04 0.85 0.78–0.92
 50–<60 1.00 0.91–1.10 0.82 0.74–0.90
 ≥60 1.05 0.92–1.20 0.74 0.65–0.85
Initial HAART regimen class
 NNRTI REF - REF -
 Boosted PI 0.77 0.73–0.82 1.03 0.98–1.09
CD4 cell count at HAART initiation
 <350 cells/μl REF - REF -
 ≥350 cells/μl 0.94 0.89–1.00 1.05 0.98–1.12
Log10 HIVRNA at HAART initiation 0.84 0.82–0.87 1.32 1.27–1.36
Sex
 Male REF - REF -
 Female 0.98 0.92–1.05 1.13 1.05–1.21
Race and ethnicity
 White REF - REF -
 Black 0.91 0.86–0.97 0.87 0.82–0.92
 Hispanic 0.94 0.86–1.02 0.87 0.79–0.95
 Other/Unknown 0.99 0.92–1.06 0.92 0.86–1.00
HIV transmission risk group
 MSM REF - REF -
 Injection drug use 0.85 0.78–0.93 0.78 0.71–0.86
 Heterosexual contact 0.92 0.85–0.99 0.86 0.79–0.93
 Other/unknown 0.88 0.81–0.96 0.88 0.81–0.96
Clinical AIDS prior to HAART initiation
 No REF - REF -
 Yes 1.04 0.97–1.11 0.94 0.88–1.01
Year of HAART initiation
 1998 REF - REF -
 1999 1.16 0.99–1.37 0.92 0.78–1.08
 2000 1.21 1.03–1.42 0.93 0.79–1.09
 2001 1.32 1.13–1.55 0.89 0.76–1.05
 2002 1.15 0.98–1.34 0.91 0.78–1.07
 2003 1.30 1.11–1.52 1.03 0.88–1.21
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Outcomes HIV-1 RNA
suppression (<500 copies/ml)
CD4 cell count increase of 100
cells/μl
 2004 1.41 1.20–1.65 0.99 0.84–1.17
 2005 1.43 1.22–1.68 1.13 0.96–1.34
 2006 1.55 1.32–1.83 1.14 0.97–1.35
 2007 2.02 1.70–2.40 1.21 1.02–1.44
 2008 2.32 1.93–2.78 1.39 1.15–1.67
AIDS acquired immune deficiency syndrome, HAART highly active antiretroviral treatment, HIV human immunodeficiency virus, NNRTI
nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor.
a
Pooled logistic regression models weighted for the first change in ART regimen class (weights at the 1st and 99th percentile were truncated) and
adjusted for cohort.
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Table 3
Adjusteda hazard odds ratios (aHOR) and 95% confidence intervals (95% CI) virologic and immunologic
response to HAART within 24 months following HAART initiation, by regimen class and age, NA-
ACCORD, 1998–2008.
aHORa NNRTI 95% CI aHORa Boosted PI 95% CI
Virologic response (HIV RNA ≤500 copies/ml)
Age (years)
 18–<30 Ref - 0.75 0.64–0.88
 30–<40 0.98 0.89–1.07 0.71 0.64–0.79
 40–<50 0.94 0.85–1.03 0.76 0.68–0.85
 50–<60 0.98 0.88–1.09 0.79 0.69–0.90
 ≥60 1.06 0.91–1.24 0.77 0.63–0.94
Immunologic response (≥100 cells/μl increase in CD4 cell count)
Age (years)
 18–<30 Ref - 0.94 0.80–1.11
 30–<40 0.90 0.82–0.99 0.96 0.86–1.07
 40–<50 0.83 0.76–0.91 0.88 0.79–0.99
 50–<60 0.80 0.72–0.90 0.84 0.73–0.96
 ≥60 0.73 0.63–0.85 0.76 0.60–0.97
AIDS acquired immune deficiency syndrome, HAART highly active antiretroviral treatment, HIV human immunodeficiency virus, NNRTI
nonnucleoside reverse transcriptase inhibitor, PI protease inhibitor.
a
Pooled logistic regression models weighted for the first change in HAART regimen class (weights at the 1st and 99th percentile were truncated)
and adjusted for CD4 cell and HIV viral load at initiation, race and ethnicity, HIV transmission risk group, sex, cohort, clinical AIDS diagnosis
prior to HAART initiation, year of HAART initiation and month from HAART initiation.
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